Clinical Research Directory

Inclusion Criteria: 1. Age ≥ 18 years old and ≤ 80 years old, gender not limited; 2. Weight ≥ 45kg; Body Mass Index (BMI) ≥ 18.5kg/m\^2; 3. Diagnosed with CKD ≥ 6 months and estimated glomerular filtration rate (eGFR) ≥ 15mL/min/1.73m\^2 before enrollment, and\<60 mL/min/1.73m\^2 (estimated GFR using CKD-EPI formula), with no expected renal replacement therapy plan during the study period; 4. rHuEPO or HIF-PHI should be used for ≥ 4 weeks and ≤ 12 weeks; 5. During the 28days and 3days before randomization, with Hb ≥ 70g/L and \< 110g/L; 6. Understand the research procedure and voluntarily sign an informed consent form (ICF) in writing. Exclusion Criteria: 1. Known to have hematological disorders or other diseases that cause anemia other than chronic kidney disease (CKD), such as primary pure red cell aplasia (PRCA), homozygous sickle cell disease, thalassemia/Cooley's anemia, multiple myeloma, hemolytic anemia, and myelodysplastic syndrome, or malignant tumors; 2. Known to be allergic to iron agents or polyethylene glycol; 3. Received red blood cell or whole blood transfusion therapy within the three months prior to randomization; 4. Have received oral or intravenous immunosuppressive or glucocorticoid therapy within the 12 weeks prior to randomization; 5. Individuals with poor blood pressure control; 6. C-reactive protein ≥ 30mg/L within the first 3 days of randomization; 7. Pregnant and lactating women, women of childbearing age who have a positive urine β - HCG test result before the trial, or those who have a pregnancy plan during the study period; 8. Assessment of cardiac function level III or IV within the first 3 days of randomization; 9. Within the first 3 days of randomization, the liver function was assessed as Grade C; 10. Researchers believe that subjects with any other factors that are not suitable for participating in this trial.